Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Indivior plc (INDV) USD0.1

Sell:120.70p Buy:121.10p 0 Change: 2.60p (2.18%)
Market closed Prices as at close on 13 August 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:120.70p
Buy:121.10p
Change: 2.60p (2.18%)
Market closed Prices as at close on 13 August 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:120.70p
Buy:121.10p
Change: 2.60p (2.18%)
Market closed Prices as at close on 13 August 2020 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia. Its products are Suboxone Film (buprenorphine and naloxone), Suboxone Tablet (buprenorphine and naloxone), and Subutex Tablet (buprenorphine). Its other products include RBP-6000 in ATRIGEL, RBP-7000 risperidone monthly depot, Arbaclofen placarbil for alcohol use disorder (AUD), Intranasal naloxone for treatment of opioid overdose and RBP-8000 cocaine esterase for cocaine intoxication. Its RBP-6000 buprenorphine monthly depot is developed for the treatment of opioid use disorder. Its RBP-7000 risperidone monthly depot is developed for treatment of schizophrenia.

Contact details

Address:
103-105 Bath Road
SLOUGH
SL1 3UH
United Kingdom
Telephone:
+44 (01753) 217800
Website:
indivior.com/

Important dates

Future events
There are no future events available.
Past events
Quarter 2 results 30 July 2020 30/07/20
Interim results 30 July 2020 30/07/20
Quarterly results 14 May 2020 14/05/20
AGM 07 May 2020 07/05/20
Trading Announcement 08 April 2020 08/04/20
Annual report 13 March 2020 13/03/20
Final results 13 February 2020 13/02/20
Quarter 3 results 31 October 2019 31/10/19

General stock information

EPIC:
INDV
ISIN:
GB00BRS65X63
Market cap:
£891.92 million
Shares in issue:
733.48 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE All Share,FTSE Small Cap

Key personnel

  • Daniel Tasse
    Interim Chairman of the Board
  • Mark Crossley
    Chief Executive Officer, Executive Director
  • Ryan Preblick
    Interim Chief Financial Officer
  • Jon Fogle
    Chief Human Resource Officer
  • Christian Heidbreder
    Chief Scientific Officer
  • Cynthia Cetani
    Chief Integrity and Compliance Officer
  • Debby Betz
    Chief Corporate Affairs and Communications Officer
  • Rosh Dias
    Chief Medical Officer
  • Javier Rodriguez
    Chief Legal Officer
  • Richard Simkin
    Chief Commercial and Strategy Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.